<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Heidelberg Pharma Ag — News on 6ix</title>
    <link>https://6ix.com/company/heidelberg-pharma-ag</link>
    <description>Latest news and press releases for Heidelberg Pharma Ag on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 24 Nov 2025 21:39:26 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/heidelberg-pharma-ag" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836048478dffbe2df13589a.webp</url>
      <title>Heidelberg Pharma Ag</title>
      <link>https://6ix.com/company/heidelberg-pharma-ag</link>
    </image>
    <item>
      <title>Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer</title>
      <link>https://6ix.com/company/heidelberg-pharma-ag/news/heidelberg-pharma-announces-changes-to-the-executive-management-board-dr-dongzhou-jeffery-liu-appointed-as-chairman-of-the-executive-board-and-chief-executive-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/heidelberg-pharma-ag/news/heidelberg-pharma-announces-changes-to-the-executive-management-board-dr-dongzhou-jeffery-liu-appointed-as-chairman-of-the-executive-board-and-chief-executive-officer</guid>
      <pubDate>Mon, 24 Nov 2025 21:39:26 GMT</pubDate>
      <description>LADENBURG, Germany - November 24, 2025 (NEWMEDIAWIRE) - Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the Supervisory Board has revoked the appointme...</description>
    </item>
    <item>
      <title>Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar</title>
      <link>https://6ix.com/company/heidelberg-pharma-ag/news/heidelberg-pharma-to-present-new-clinical-data-of-lead-adc-candidate-hdp-101-at-the-world-adc-congress-2025-and-to-host-webinar</link>
      <guid isPermaLink="true">https://6ix.com/company/heidelberg-pharma-ag/news/heidelberg-pharma-to-present-new-clinical-data-of-lead-adc-candidate-hdp-101-at-the-world-adc-congress-2025-and-to-host-webinar</guid>
      <pubDate>Mon, 03 Nov 2025 21:48:18 GMT</pubDate>
      <description>Objective responses and promising anti-tumor activity observed in several patients across multiple cohorts in the ongoing Phase I/IIa clinical trial Data reinforces the therapeutic potential and safety profile of HDP-101 in relapsed or refractor...</description>
    </item>
    <item>
      <title>Heidelberg Pharma to Present at the Life Sciences Virtual Investor Forum June 12th</title>
      <link>https://6ix.com/company/heidelberg-pharma-ag/news/heidelberg-pharma-to-present-at-the-life-sciences-virtual-investor-forum-june-12th</link>
      <guid isPermaLink="true">https://6ix.com/company/heidelberg-pharma-ag/news/heidelberg-pharma-to-present-at-the-life-sciences-virtual-investor-forum-june-12th</guid>
      <pubDate>Fri, 06 Jun 2025 12:35:00 GMT</pubDate>
      <description>Heidelberg Pharma invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.comLADENBURG, Germany, June 06, 2025 (GLOBE NEWSWIRE) -- Heidelberg Pharma AG (XETRA: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that Andreas Pahl, CEO of Heidelberg Pharma, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on June</description>
    </item>
  </channel>
</rss>